Suven Life Sciences announces today that the grant of one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with  Neurodegenerative diseases and these Patents are valid through 2034.

The granted claims of the patents include the class of selective 5-HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' says Venkat Jasti, CEO of Suven.  

Shares of the company gained Rs 1.6, or 0.94%, to trade at Rs 172.55. The total volume of shares traded was 9,126 at the BSE (11.50 a.m., Friday).